These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2986 related articles for article (PubMed ID: 33508918)

  • 41. A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study): A Turkish Oncology Group Study.
    Abali H; Yalcin S; Onal HC; Dane F; Oksuzoglu B; Ozdemir N; Mertsoylu H; Artac M; Camci C; Karabulut B; Basal FB; Budakoglu B; Sendur MAN; Goktas B; Ozdener F; Baygul A
    Am J Clin Oncol; 2021 Jul; 44(7):301-307. PubMed ID: 33979100
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and feasibility of total laparoscopic radical resection of Siewert type II gastroesophageal junction adenocarcinoma through the left diaphragm and left thoracic auxiliary hole.
    Huang Y; Liu G; Wang X; Zhang Y; Zou G; Zhao Z; Cao Z; Zhao H; Yuan X; Zhang C
    World J Surg Oncol; 2021 Mar; 19(1):73. PubMed ID: 33714262
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction.
    Zhao Q; Li Y; Wang J; Zhang J; Qiao X; Tan B; Tian Y; Shi G; Xu Q; Li R; Liu Y; Yang P
    Am J Med Sci; 2015 Jun; 349(6):472-6. PubMed ID: 25996101
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage.
    Shin K; Park SJ; Lee J; Park CH; Song KY; Lee HH; Seo HS; Jung YJ; Park JM; Lee SH; Roh SY; Kim IH
    BMC Cancer; 2019 Dec; 19(1):1232. PubMed ID: 31852475
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Application value of texture analysis of magnetic resonance images in prediction of neoadjuvant chemoradiotherapy efficacy for rectal cancer].
    Shu Z; Fang S; Ding Z; Mao D; Pang P; Gong X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1051-1058. PubMed ID: 30269327
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Transthoracic single-port-assisted laparoscopic gastrectomy versus laparoscopic transhiatal approach for Siewert type II adenocarcinoma of the esophagogastric junction: a single-center retrospective study.
    Li J; Xiong W; Ou H; Yang T; Jiang S; Huang H; Zheng Y; Luo L; Peng X; Wang W
    Surg Endosc; 2024 Apr; 38(4):1986-1994. PubMed ID: 38381159
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Postoperative complications and their influence on the prognosis factors in gastric cancer patients receiving neoadjuvant treatment].
    Wang TB; Mao QK; Zhang XJ; Zhou H; Guo CG; Chen YT; Zhao DB
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):160-166. PubMed ID: 33508922
    [No Abstract]   [Full Text] [Related]  

  • 48. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol.
    Cheng X; Wu D; Xu N; Chen L; Yan Z; Chen P; Zhou L; Yu J; Cui J; Li W; Wang C; Feng W; Wei Y; Yu P; Du Y; Ying J; Xu Z; Yang L; Zhang Y
    BMC Cancer; 2021 Jan; 21(1):56. PubMed ID: 33435909
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Five-step maneuver of transthoracic single-port assisted laparoscopic lower mediastinal lymph node dissection for Siewert type Ⅱ adenocarcinoma of the esophagogastric junction].
    Luo SJ; Xiong WW; Chen Y; Li ZY; Li E; Zeng HP; Zheng YS; Luo LJ; Li J; Cui ZM; Wan J; Wang W
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Aug; 24(8):684-690. PubMed ID: 34412185
    [No Abstract]   [Full Text] [Related]  

  • 50. [Clinical features and prognosis analysis of 21 gastric cancer patients with pathological complete response after neoadjuvant chemotherapy].
    Peng L; Yang W; Zhang Z; Liu H; Hua Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Oct; 20(10):1168-1173. PubMed ID: 29130233
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical comparison of antrum-preserving double tract reconstruction vs roux-en-Y reconstruction after gastrectomy for Siewert types II and III adenocarcinoma of the esophagogastric junction.
    Xiao JW; Liu ZL; Ye PC; Luo YJ; Fu ZM; Zou Q; Wei SJ
    World J Gastroenterol; 2015 Sep; 21(34):9999-10007. PubMed ID: 26379405
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of Long-Term Efficacy in S-1 and Capecitabine With Oxaliplatin as Adjuvant Chemotherapy for Patients With Gastric Cancer After Curative Surgery: A Retrospective, Single-Center Observational Study.
    Oh SE; An JY; Choi MG; Lee JH; Sohn TS; Bae JM
    Technol Cancer Res Treat; 2021; 20():15330338211039679. PubMed ID: 34605706
    [No Abstract]   [Full Text] [Related]  

  • 53. Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study.
    Zhu J; Liu F; Gu W; Lian P; Sheng W; Xu J; Cai G; Shi D; Cai S; Zhang Z
    Radiat Oncol; 2014 Mar; 9():70. PubMed ID: 24606870
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel abdominal approach for dissection of advanced type II/III adenocarcinoma of the esophagogastric junction: a new surgical option.
    Hu C; Zhu HT; Xu ZY; Yu JF; Du YA; Huang L; Yu PF; Wang LJ; Cheng XD
    J Int Med Res; 2019 Jan; 47(1):398-410. PubMed ID: 30296865
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Can Clinical Stage in the 8
    Watanabe H; Hasegawa S; Kumazu Y; Hashimoto I; Komori K; Suematsu H; Kano K; Fujikawa H; Aoyama T; Yamada T; Yukawa N; Yoshikawa T; Rino Y; Saito A; Ogata T; Oshima T
    In Vivo; 2023; 37(4):1790-1796. PubMed ID: 37369497
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical Analysis of the Efficacy and Safety of Different Neoadjuvant Strategies in the Treatment of Locally Advanced Rectal Cancer.
    Chen W; Wang W; Huang S; Zhou L; Wang G; Chen W
    Cancer Invest; 2024 Aug; 42(7):661-670. PubMed ID: 39037150
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Does Adjuvant Chemotherapy for Locally Advanced Resectable Rectal Cancer treated with Neoadjuvant Chemoradiotherapy have an impact on survival? A Single Moroccan Institute Retrospective Study.
    Seddik Y; Brahmi SA; Afqir S
    Gulf J Oncolog; 2019 May; 1(30):29-32. PubMed ID: 31242979
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Effect of splenic hilar lymphadenectomy on locally advanced Siewert type Ⅱ and Ⅲ adenocarcinoma of esophagogastric junction with a tumor diameter ≥4 cm: a five-year survival analysis].
    Lin JX; Wu D; Jiang YM; Chen JY; Lin GT; Li P; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Zheng CH; Huang CM
    Zhonghua Wai Ke Za Zhi; 2022 Sep; 60(9):853-859. PubMed ID: 36058712
    [No Abstract]   [Full Text] [Related]  

  • 59. Utility of robotic surgery for Siewert type II/III adenocarcinoma of esophagogastric junction: transhiatal robotic versus laparoscopic approach.
    Nishi M; Wada Y; Yoshikawa K; Takasu C; Tokunaga T; Nakao T; Kashihara H; Yoshimoto T; Shimada M
    BMC Surg; 2023 May; 23(1):128. PubMed ID: 37194030
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Establishment of prognostic models for adenocarcinoma of oesophagogastric junction patients with neoadjuvant chemoradiotherapy: a real-world study.
    Du R; Ming J; Geng J; Zhu X; Zhang Y; Li S; Liu Z; Wang H; Wang Z; Tang L; Zhang X; Wu A; Bu Z; Yan Y; Li Z; Li Y; Li Z; Wang W
    Radiat Oncol; 2022 Mar; 17(1):45. PubMed ID: 35241109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 150.